Cardiomegaly and vasoactive hormones in rats with chronic myocardial infarction: long-term effects of chlorothiazide

M Kohzuki1, M Kanazawa, K Yoshida

  • 1Section of Internal Medicine and Disability Prevention, Tohoku University Graduate School, Sendai, Japan.

Insights

Chlorothiazide treatment did not prevent cardiac hypertrophy in rats with heart failure. This diuretic therapy did not alter body sodium or vasoactive hormones, suggesting the renin-angiotensin system activation may limit its effectiveness.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Chronic left ventricular failure can lead to cardiac hypertrophy.
  • The role of vasoactive hormones and body sodium in heart failure requires further investigation.

Purpose of the Study:

  • To examine the effects of chlorothiazide on cardiac hypertrophy, vasoactive hormones, and body sodium in a rat model of chronic heart failure.
  • To determine if chlorothiazide therapy can prevent or reverse cardiac hypertrophy in this model.

Main Methods:

  • Rats with chronic myocardial infarction were treated with chlorothiazide or placebo for 4 weeks.
  • Measurements included cardiac weight, exchangeable body sodium, plasma renin activity, plasma vasopressin, plasma osmolality, and plasma atrial natriuretic peptide.

Main Results:

  • Untreated rats with infarction showed increased cardiac weight, indicating left ventricular dysfunction.
  • Chlorothiazide increased hematocrit and plasma renin activity but did not affect body sodium, vasopressin, or osmolality.
  • Plasma atrial natriuretic peptide was elevated in infarcted rats, unaffected by chlorothiazide.
  • Chlorothiazide did not prevent or reverse cardiac hypertrophy.

Conclusions:

  • Prolonged chlorothiazide therapy did not impact cardiac hypertrophy, body sodium, or key vasoactive hormones in this experimental heart failure model.
  • The lack of effect may be attributed to concurrent activation of the renin-angiotensin system.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...